Molecular Genetics Group, Universidad de Antioquia, Calle 70, N° 52-21, A.A, 1226, Medellin, Colombia; Department of Physiology and Biochemistry, School of Medicine, Universidad de Antioquia, Calle 70, N° 52-21, A.A, 1226, Medellin, Colombia.
Department of Physiology and Biochemistry, School of Medicine, Universidad de Antioquia, Calle 70, N° 52-21, A.A, 1226, Medellin, Colombia.
J Ethnopharmacol. 2021 Jan 30;265:113298. doi: 10.1016/j.jep.2020.113298. Epub 2020 Aug 26.
Eucalyptus tereticornis Sm. (Eu) is a plant species used in traditional medicine to treat diabetes mellitus. Eu leaf extracts have been shown to regulate immuno-metabolic activities that are associated with obesity and insulin resistance. OBE100 and OBE104 are two natural Eu extracts that are rich in pentacyclic triterpenes. The major compounds identified in OBE100 are ursolic acid (UA), oleanolic acid (OA), and ursolic acid lactone (UAL), and the major compounds identified in OBE104 are UA and OA.
This study aimed to investigate the effects of two extracts from Eu leaves with different triterpene composition in a nutritional animal model of prediabetes.
A mouse model of diet-induced obesity was used to analyze the effects of the OBE100 and OBE104 treatments on metabolic markers and gene expression in liver and visceral adipose tissue.
Treating the prediabetic mouse model with OBE100 and OBE104 increased glucose tolerance. However, only the Eu extract that contained three triterpenes reduced mouse body weight, hepatic and adipose fat content, and plasma lipid levels. OBE100 treatment also led to decreased hepatic mRNA levels of PPARA, CPT1A, and SERBP1. In visceral adipose tissue, OBE100 treatment reduced expression of PPARA and ACACA and increased UCP1 expression.
These results suggest that developing a new multitargeting bioactive compound from the natural extract from Eu may help combat obesity and diabetes. Treatment with OBE100 had better effects than OBE104 in a diet-induced obesity mouse model, suggesting that the OBE100 extract, which contains three triterpenes, may be beneficial in combating obesity.
桉树（Eu）是一种用于治疗糖尿病的传统医学植物物种。Eu 叶提取物已被证明可调节与肥胖和胰岛素抵抗相关的免疫代谢活性。OBE100 和 OBE104 是两种富含五环三萜的天然 Eu 提取物。在 OBE100 中鉴定出的主要化合物是熊果酸（UA）、齐墩果酸（OA）和熊果酸内酯（UAL），而在 OBE104 中鉴定出的主要化合物是 UA 和 OA。
本研究旨在研究两种具有不同三萜组成的 Eu 叶提取物在糖尿病前期营养动物模型中的作用。
使用饮食诱导肥胖的小鼠模型来分析 OBE100 和 OBE104 处理对肝脏和内脏脂肪组织代谢标志物和基因表达的影响。
用 OBE100 和 OBE104 治疗糖尿病前期小鼠模型可提高葡萄糖耐量。然而，只有含有三种三萜的 Eu 提取物可降低小鼠体重、肝和脂肪组织脂肪含量以及血浆脂质水平。OBE100 处理还导致肝脏中 PPARA、CPT1A 和 SERBP1 的 mRNA 水平降低。在内脏脂肪组织中，OBE100 处理降低了 PPARA 和 ACACA 的表达，并增加了 UCP1 的表达。
这些结果表明，从 Eu 的天然提取物中开发新的多靶点生物活性化合物可能有助于对抗肥胖和糖尿病。在饮食诱导肥胖的小鼠模型中，OBE100 的治疗效果优于 OBE104，这表明含有三种三萜的 OBE100 提取物可能有益于对抗肥胖。
